HC Wainwright Issues Optimistic Estimate for RLMD Earnings

Relmada Therapeutics, Inc. (NASDAQ:RLMD – Free Report) – Research analysts at HC Wainwright upped their Q4 2026 earnings per share (EPS) estimates for shares of Relmada Therapeutics in a note issued to investors on Friday, November 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.09) for the quarter, up from their prior forecast of ($0.14). The consensus estimate for Relmada Therapeutics’ current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for Relmada Therapeutics’ Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.14) EPS, Q4 2027 earnings at ($0.15) EPS, FY2027 earnings at ($0.52) EPS, FY2028 earnings at ($0.45) EPS, FY2029 earnings at ($0.51) EPS and FY2030 earnings at $0.01 EPS.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Relmada Therapeutics in a research note on Monday, September 14th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

Read Our Latest Research Report on Relmada Therapeutics

Relmada Therapeutics Trading Down 5.0%

RLMD stock opened at $2.86 on Tuesday. Relmada Therapeutics has a twelve month low of $2.85 and a twelve month high of $8.00. The company has a market capitalization of $305.15 million, a P/E ratio of -3.97 and a beta of 0.62. The firm has a 50 day simple moving average of $3.70 and a 200-day simple moving average of $5.32.

Relmada Therapeutics (NASDAQ:RLMD – Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02.

Insiders Place Their Bets

In other news, CFO Maged Shenouda acquired 79,800 shares of the business’s stock in a transaction on Thursday, September 10th. The shares were purchased at an average price of $4.25 per share, for a total transaction of $339,150.00. Following the completion of the purchase, the chief financial officer directly owned 1,000,000 shares of the company’s stock, valued at $4,250,000. This represents a 8.67% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 14.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in RLMD. Legal & General Group Plc bought a new position in Relmada Therapeutics during the second quarter worth $64,000. AXQ Capital LP acquired a new position in Relmada Therapeutics in the second quarter worth $84,000. State of Wyoming acquired a new stake in shares of Relmada Therapeutics during the first quarter worth $88,000. Keebeck Wealth Management acquired a new stake in shares of Relmada Therapeutics during the first quarter worth $90,000. Finally, The Manufacturers Life Insurance Company bought a new position in shares of Relmada Therapeutics in the 2nd quarter worth about $173,000. Institutional investors and hedge funds own 45.24% of the company’s stock.

More Relmada Therapeutics News

Here’s some of the latest news about RLMD:

  • Positive Sentiment: HC Wainwright raised its estimates across several periods, including reducing its projected losses for FY2027 to $0.52 per share from $0.61 and for FY2028 to $0.45 from $0.52. It also moved its FY2030 forecast to a profit of $0.01 per share from a loss of $0.06. These revisions suggest a more favorable longer-term earnings outlook. HC Wainwright estimate changes
  • Neutral Sentiment: Relmada appointed Jørn Skibsted Jakobsen as chief development officer. The hire adds development leadership, but the announcement as provided does not include details of a pipeline milestone or expected financial impact. Relmada appoints Jørn Skibsted Jakobsen as CDO

About Relmada Therapeutics

(Get Free Report)

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company developing investigational treatments for central nervous system disorders, with a focus on depression. The company’s work centers on advancing drug candidates through clinical research; it does not have an approved commercial product. Its best-known candidate, REL-1017 (esmethadone), is an oral compound that acts on NMDA receptors. Relmada has studied it as an add-on treatment for adults with major depressive disorder who have not responded adequately to existing antidepressants.

Recommended Stories

Earnings History and Estimates for Relmada Therapeutics (NASDAQ:RLMD)

Receive News & Ratings for Relmada Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relmada Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.